Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology

1998 Saylor, 2009, Monoclonal antibody-based therapies for microbial diseases, Vaccine, 27S, G38, 10.1016/j.vaccine.2009.09.105 Marasco, 2007, The growth and potential of human antiviral monoclonal antibody therapeutics, Nat. Biotechnol., 25, 1421, 10.1038/nbt1363 2005 Lowy, 2010, Treatment with monoclonal antibodies against Clostridium difficile toxins, N. Engl. J. Med., 362, 197, 10.1056/NEJMoa0907635 Beerli, 2010, Mining human antibody repertoires, MAbs, 2, 365, 10.4161/mabs.12187 Berry, 2005, Rational monoclonal antibody development to emerging pathogens, biothreat agents and foreign animal disease: the antigen scale, Vet. J., 170, 193, 10.1016/j.tvjl.2004.04.021 Burton, 2001, A model for neutralization of viruses based on antibody coating of the virion surface, Curr. Top. Microbiol. Immunol., 260, 109 Imai, 1998, Fusion of influenza virus with the endosomal membrane is inhibited by monoclonal antibodies to defined epitopes on the hemagglutinin, Virus Res., 53, 129, 10.1016/S0168-1702(97)00143-3 Webster, 1967, Preparation and properties of antibody directed specifically against the neuraminidase of influenza virus, J. Immunol., 99, 49 Moragues, 2003, A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti-C. albicans activities, Infect. Immun., 71, 5273, 10.1128/IAI.71.9.5273-5279.2003 McClelland, 2010, Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism, J. Clin. Invest., 120, 1355, 10.1172/JCI38322 Orange, 2006, Use of intravenous immunoglobulin in human disease: a review of evidence by members of the primary immunodeficiency committee of the American academy of allergy, asthma and immunology, J. Allergy Clin. Immunol., 117, S524, 10.1016/j.jaci.2006.01.015 ter Meulen, 2007, Monoclonal antibodies for prophylaxis and therapy of infectious diseases, Expert Opin. Emerg. Drugs, 12, 525, 10.1517/14728214.12.4.525 Plotkin, 2008, Countering anthrax: vaccines and immunoglobulins, Clin. Infect. Dis., 46, 129, 10.1086/523578 Couderc, 2009, Prophylaxis and therapy for Chikungunya virus infection, J Infect Dis, 200, 516, 10.1086/600381 Wu, 2008, Immunoprophylaxis of RSV infection: advancing from RSV-IVIG to palivizumab and motavizumab, Curr. Top. Microbiol. Immunol., 317, 103 Casadevall, 1995, Return to the past: the case for antibody-based therapies in infectious diseases, Clin. Infect. Dis., 21, 150, 10.1093/clinids/21.1.150 Burdick, 2006, Clearance of prions during plasma protein manufacture, Transfus Med. Rev., 20, 57, 10.1016/j.tmrv.2005.08.005 Jefferis, 2005, Glycosylation of recombinant antibody therapeutics, Biotechnol. Progress, 21, 11, 10.1021/bp040016j Salfeld, 2007, Isotype selection in antibody engineering, Nat. Biotechnol., 25, 1369, 10.1038/nbt1207-1369 Johnson, 2010, Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus, J. Infect. Dis., 176, 1215, 10.1086/514115 Beck, 2009, Therapeutic antibodies and related products: choosing the right structure for success, Med. Sci. (Paris), 12, 1024, 10.1051/medsci/200925121024 Dechant, 2002, Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing, Blood, 100, 4574, 10.1182/blood-2002-03-0687 Lendvai, 2000, Mechanism for the isotype dependence of antibody-mediated toxicity in Cryptococcus neoformans-infected mice, J. Immunol., 164, 4367, 10.4049/jimmunol.164.8.4367 Sarvas, 1990, Effect of Gm allotypes on IgG2 antibody responses and IgG2 concentrations in children and adults, Infect. Immunol., 2, 317 Jefferis, 2007, Antibody therapeutics: isotype and glycoform selection, Expert Opin. Biol. Ther., 7, 1401, 10.1517/14712598.7.9.1401 van der Zee, 1986, Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency, J. Immunol., 137, 3566 Spiegelberg, 1989, Biological role of different antibody classes, Int. Arch. Allergy Appl. Immunol., 90, 22, 10.1159/000235071 Horn, 2010, Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11, Antimicrob. Agents Chemother., 54, 2338, 10.1128/AAC.01142-09 Tchoudakova, 2009, High level expression of functional human IgMs in human PER.C6® cells, MAbs, 1, 1, 10.4161/mabs.1.2.7945 Ye, 2010, Intranasal delivery of an IgA monoclonal antibody effective against sublethal H5N1 influenza virus infection in mice, Clin. Vaccine Immunol., 17, 1363, 10.1128/CVI.00002-10 Chen, 2009, Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils, Nat. Immunol., 10, 889, 10.1038/ni.1748 Beenhouwer, 2007, Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3 protect mice against Cryptococcus neoformans, Infect. Immun., 75, 1424, 10.1128/IAI.01161-06 Westerman, 2005, Serum IgG mediates mucosal immunity against rotavirus infection, Proc. Natl. Acad. Sci. U.S.A., 102, 7268, 10.1073/pnas.0502437102 Lazar, 2006, Engineered antibody Fc variants with enhanced effector function, Proc. Natl. Acad. Sci. U.S.A., 103, 4005, 10.1073/pnas.0508123103 Jefferis, 2009, Glycosylation as a strategy to improve antibody-based therapeutics, Nat. Rev. Drug Discov., 8, 226, 10.1038/nrd2804 Taylor, 1997, Bispecific monoclonal antibody complexes facilitate erythrocyte binding and liver clearance of a prototype particulate pathogen in a monkey model, J. Immunol., 159, 4035 Lindorfer, 2001, Targeting of Pseudomonas aeruginosa in the bloodstream with bispecific monoclonal antibodies, J. Immunol., 167, 2240, 10.4049/jimmunol.167.4.2240 Dadachova, 2003, Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection, Proc. Natl. Acad. Sci. U.S.A., 100, 10942, 10.1073/pnas.1731272100 Dadachova, 2004, Susceptibility of the human pathogenic fungi Cryptococcus neoformans and Histoplasma capsulatum to gamma-radiation versus radioimmunotherapy with alpha- and beta-emitting radioisotopes, J. Nucl. Med., 45, 313 Dadachova, 2004, Feasibility of radioimmunotherapy of experimental pneumococcal infection, Antimicrob. Agents Chemother., 48, 1624, 10.1128/AAC.48.5.1624-1629.2004 Little, 2002, Antiretroviral-drug resistance among patients recently infected with HIV, N. Engl. J. Med., 347, 385, 10.1056/NEJMoa013552 Velicer, 2004, Antibiotic use in relation to the risk of breast cancer, JAMA, 291, 827, 10.1001/jama.291.7.827 Kozyrsky, 2007, Increased risk of childhood asthma from antibiotic use in early life, Chest, 131, 1753, 10.1378/chest.06-3008 Pai, 2009, Progress towards recombinant anti-infective antibodies, Recent Pat. Antiinfect. Drug Discov., 4, 1, 10.2174/157489109787236319 Guo, 2006, Breaking the one antibody-one target axiom, Proc. Natl. Acad. Sci. U.S.A., 29, 11009, 10.1073/pnas.0603822103 Popkov, 2009, Instant immunity through chemically programmable vaccination and covalent self-assembly, Proc. Natl. Acad. Sci. U.S.A., 106, 4378, 10.1073/pnas.0900147106 Sepulveda, 2010, Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents, Infect. Immun., 78, 756, 10.1128/IAI.01084-09 Fattom, 2004, Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in a hemodialysis patient, Vaccine, 23, 656, 10.1016/j.vaccine.2004.06.043 Kaufman, 2006, Veronate (Inhibitex), Curr. Opin. Invest. Drugs, 7, 172 Hall, 2003, Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A, Infect. Immun., 71, 6864, 10.1128/IAI.71.12.6864-6870.2003 Vernachio, 2003, Anti-clumping factor A immunoglobulin reduces the duration of methicillin-resistant Staphylococcus aureus bacteremia in an experimental model of infective endocarditis, Antimicrob. Agents Chemother., 47, 3400, 10.1128/AAC.47.11.3400-3406.2003 Bubeck Wardenburg, 2007, Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia, Nat. Med., 13, 1405, 10.1038/nm1207-1405 Lorenz, 2011, Functional antibodies targeting IsaA of Staphylococcus aureus augment host immune response and open new perspectives for antibacterial therapy, Antimicrob. Agents Chemother., 55, 165, 10.1128/AAC.01144-10 Kelly-Quintos, 2006, Characterization of the opsonic and protective activity against Staphylococcus aureus of fully human monoclonal antibodies specific for the bacterial surface polysaccharide poly-N-acetylglucosamine, Infect. Immun., 74, 2742, 10.1128/IAI.74.5.2742-2750.2006 Park, 2008, Infection control by antibody disruption of bacterial quorum sensing signalling, Chem. Biol., 14, 1119, 10.1016/j.chembiol.2007.08.013 Neely, 2005, Passive anti-pcrv treatment protects burned mice against Pseudomonas aeruginosa challenge, Burns, 31, 153, 10.1016/j.burns.2004.09.002 Imamura, 2007, Effect of anti-pcrv antibody in a murine chronic airway Pseudomonas aeruginosa infection model, Eur. Respir. J., 29, 965, 10.1183/09031936.00147406 Rachini, 2007, An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo, Infect. Immun., 75, 5085, 10.1128/IAI.00278-07 Torosantucci, 2005, A novel glyco-conjugate vaccine against fungal pathogens, J. Exp. Med., 202, 597, 10.1084/jem.20050749 Throsby, 2008, Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells, PLoS One, 4, e3942, 10.1371/journal.pone.0003942 Sui, 2009, Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses, Nat. Struct. Mol. Biol., 16, 265, 10.1038/nsmb.1566 Sui, 2008, Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway, PLoS Pathog., 4, e1000197, 10.1371/journal.ppat.1000197 Rockx, 2008, Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge, J. Virol., 82, 3220, 10.1128/JVI.02377-07 Shrestha, 2010, The development of therapeutic antibodies that neuralize homologous and heterologous genotypes of dengue virus type 1, PLoS Pathog., 6, e1000823, 10.1371/journal.ppat.1000823 Radoshitzky, 2007, Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses, Nature, 446, 92, 10.1038/nature05539 Evans, 2007, Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry, Nature, 446, 801, 10.1038/nature05654 Glass, 2005, Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection, J. Exp. Med., 202, 1087, 10.1084/jem.20042530 Soares, 2008, Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases, Nat. Med., 14, 1357, 10.1038/nm.1885 McKeating, 1989, Characterization of the HIV-1 neutralization escape mutants, AIDS, 3, 777, 10.1097/00002030-198912000-00001 Keck, 2009, Mutations in hepatitis C virus E2 located outsie the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity, J. Virol., 83, 6149, 10.1128/JVI.00248-09 Zharikova, 2005, Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2, J. Virol., 79, 6644, 10.1128/JVI.79.11.6644-6654.2005 Logtenberg, 2007, Antibody cocktails: next-generation biopharmaceuticals with improved potency, Trends Biotechnol., 25, 390, 10.1016/j.tibtech.2007.07.005 Prabakaran, 2009, Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants, PLoS One, 4, e5672, 10.1371/journal.pone.0005672 Meulen, 2006, Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants, PLoS Med., 3, e237, 10.1371/journal.pmed.0030237 Seiler, 2009, In vivo selection of neutralization-resistant virus variants but no evidence of B cell tolerance in lymphocyttic choriomeningitis virus carrier mice expressing a transgenic virus-neutralizing antibody, J. Immunol., 162, 4536 Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection. March 6, 2007. http://www.clinicaltrials.gov/show/NCT00300807 Bregenholt, 2007, Recombinant human polyclonal antibodies: a new class of therapeutic antibodies against viral infections, Curr. Pharm. Des., 12, 2007, 10.2174/138161206777442173 Bakker, 2005, Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants, J. Virol., 79, 9062, 10.1128/JVI.79.14.9062-9068.2005 de Kruif, 2007, A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis, Annu. Rev. Med., 58, 359, 10.1146/annurev.med.58.061705.145053 Goudsmit, 2006, Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin, J. Infect. Dis., 193, 796, 10.1086/500470 Burton, 2004, HIV vaccine design and the neutralizing antibody problem, Nat. Immunol., 5, 233, 10.1038/ni0304-233 Law, 2008, Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge, Nat. Med., 14, 25, 10.1038/nm1698 White, 2003, Monoclonal antibodies inhibit prion replication and delay the development of prion disease, Nature, 422, 80, 10.1038/nature01457 Rhys Jones, 2010, A camelid anti-PrP antibody abrogates PrPSc replication in prion-permissive neuroblastoma cell lines, PLoS One, 5, e9804, 10.1371/journal.pone.0009804 Prescott, 2010, Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review, Pharmacoeconomics, 28, 279, 10.2165/11531860-000000000-00000 Nielsen, 2010, Single-batch production of recombinant human polyclonal antibodies, Mol. Biotechnol., 45, 257, 10.1007/s12033-010-9270-9 Pogue, 2010, Production of pharmaceutical-grade recombinant aprotinin and a monoclonal antibody product using plant-based transient expression systems, Plant Biotechnol. J., 8, 638, 10.1111/j.1467-7652.2009.00495.x Kuroiwa, 2009, Antigen-specific human polyclonal antibodies from hyperimmunized cattle, Nat. Biotechnol., 27, 173, 10.1038/nbt.1521 Kuczewski, 2011, A single-use purification process for the production of a monoclonal antibody produced in a PER.C6 human cell line, Biotechnol. J., 6, 56, 10.1002/biot.201000292 Baer, 2009, An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity, Infect. Immun., 77, 1083, 10.1128/IAI.00815-08 Frank, 2002, Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV, J. Infect. Dis., 186, 64, 10.1086/341069 Dharmasena, 2009, Characterization of a novel protective monoclonal antibody that recognizes an epitope common to Vibrio cholerae Ogawa and Inaba serotypes, Microbiology, 155, 2353, 10.1099/mic.0.025726-0 Xiao, 2010, Human anti-plague monoclonal antibodies protect mice from Yersinia pestis in a bubonic plague model, PLoS One, 5, e13047, 10.1371/journal.pone.0013047 Wang, 2010, Passive protection of purified yolk immunoglobulin administered against Shiga toxin 1 in mouse models, Can. J. Microbiol., 56, 1003, 10.1139/W10-087 Pratt, 2007, Oropharyngeal aspiration of ricin as a lung challenge model for evaluation of the therapeutic index of antibodies against ricin A-chain for post-exposure treatment, Exp. Lung Res., 33, 459, 10.1080/01902140701731805 http://www.cangene.com http://www.hgsi.com Migone, 2009, Raxibacumab for the treatment of inhalational anthrax, N. Engl. J. Med., 361, 135, 10.1056/NEJMoa0810603 Mohamed, 2005, A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge, Infect. Immun., 73, 795, 10.1128/IAI.73.2.795-802.2005 http://www.pharmathene.com Vitale, 2006, Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity, Infect. Immun., 74, 5840, 10.1128/IAI.00712-06 Cotter, 1995, Protective efficacy of major outer membrane protein-specific immunoglobulin A (IgA) and IgG monoclonal antibodies in a murine model of Chlamydia trachomatis genital tract infection, Infect. Immun., 63, 4704, 10.1128/iai.63.12.4704-4714.1995 http://www.alopexx.com Centers for Disease Control and Prevention (CDC), 2010, Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin, Morb. Mortal Wkly. Rep., 59, 299 Garcia-Rodriguez, 2010, Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin, Protein Eng. Des. Sel., 13, 1 http://www.xoma.com http://www.progenics.com http://www.medimmune.ca Morris, 2009, A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection, BMC Infect. Dis., 9, 106, 10.1186/1471-2334-9-106 Centers for Disease Control and Prevention (CDC), 2006, A new product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol, Morb. Mortal Wkly. Rep., 55, 209 Wittek, 2006, Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy, Int. J. Infect. Dis., 10, 193, 10.1016/j.ijid.2005.12.001 http://www.nabi.com Beeler, 2009, Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function, J. Virol., 63, 2941, 10.1128/jvi.63.7.2941-2950.1989 Rajamanonmani, 2009, On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes, J. Gen. Virol., 90, 799, 10.1099/vir.0.006874-0 Shrestha, 2010, The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1, PLoS Pathog., 6, e1000823, 10.1371/journal.ppat.1000823 Hessell, 2009, Broadly neutralizing monoclonal antibodies 2F5 and 4E10, directed against the human immunodeficiency virus type 1 (HIV-1) gp41 membrane proximal external region (MPER), protect against SHIVBa-L mucosal challenge, J. Virol., 84, 1302, 10.1128/JVI.01272-09 Hessell, 2009, Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers, PLoS Pathog., 5, e1000433, 10.1371/journal.ppat.1000433 Hessell, 2009, Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques, Nat. Med., 15, 951, 10.1038/nm.1974 Wilson, 2000, Epitopes involved in antibody-mediated protection from Ebola virus, Science, 287, 1664, 10.1126/science.287.5458.1664 Shedlock, 2010, Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms, Virology, 401, 228, 10.1016/j.virol.2010.02.029 Zhu, 2008, Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody, J. Infect. Dis., 197, 846, 10.1086/528801 Wang, 2008, Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein, Antiviral Res., 80, 168, 10.1016/j.antiviral.2008.06.002 Beerli, 2009, Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein, Virol. J., 6, 224, 10.1186/1743-422X-6-224 http://www.talecris.com http://www.cslplasma.com http://www.bayer.com http://www.baxter.com Buissa-Filho, 2008, The monoclonal antibody against the major diagnostic antigen of Paracoccidioides brasiliensis mediates immune protection in infected BALB/c mice challenged intratracheally with the fungus, Infect. Immun., 76, 3321, 10.1128/IAI.00349-08 Shapiro, 2002, Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3, Infect. Immun., 70, 2598, 10.1128/IAI.70.5.2598-2604.2002 Chaturvedi, 2005, Monoclonal immunoglobulin G1 directed against Aspergillus fumigatus cell wall glycoprotein protects against experimental murine aspergillosis, Clin. Diagn. Lab. Immunol., 12, 1063 Cabezas, 2010, Potential of anti-Candida antibodies in immunoprophylaxis, Immunotherapy, 2, 171, 10.2217/imt.09.76 Gigliotti, 2009, Passive intranasal monoclonal antibody prophylaxis against murine pneumocystis carinii pneumonia, Infect. Immun., 70, 1069, 10.1128/IAI.70.3.1069-1074.2002 Van Wye, 1990, Pseudomonas hyperimmune globulin passive immunotherapy for pulmonary exacerbations in cystic fibrosis, Pediatr. Pulmonol., 9, 7, 10.1002/ppul.1950090104 Douzinas, 2000, Prevention of infection in multiple trauma patients by high-dose intravenous immunoglobulins, Crit. Care Med., 28, 8, 10.1097/00003246-200001000-00002 Dalhoff, 1984, Synergy between acylureidopenicillins and immunoglobulin G in experimental animals, Am. J. Med., 76, 91, 10.1016/0002-9343(84)90326-7 Fomsgaard, 1993, Effect of a human IgG preparation rich in antibodies to a wide range of lipopolysaccharides on gram-negative bacterial sepsis in burned mice, APMIS, 101, 229, 10.1111/j.1699-0463.1993.tb00105.x Dalhoff, 1983, Mode of interaction between immunoglobulin G and mezlocillin against beta-lactamase producing bacteria, Arzneimittelforschung, 33, 1666 Akiyama, 2000, Antibacterial properties of Pseudomonas aeruginosa immunotype 1 lipopolysaccharide-specific monoclonal antibody (MAb) in a murine thigh infection model: combined effects of MAb and ceftazidime, Microbiol. Immunol., 44, 629, 10.1111/j.1348-0421.2000.tb02543.x Felts, 2000, Locally delivered antibodies combined with systemic antibiotics confer synergistic protection against antibiotic-resistant burn wound infection, J. Trauma, 49, 873, 10.1097/00005373-200011000-00014 Barekzi, 2000, Locally delivered polyclonal antibodies potentiate intravenous antibiotic efficacy against gram-negative infections, Pharm. Res., 19, 1801, 10.1023/A:1021481122011 Peterson, 2006, Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax, Infect. Immun., 74, 1016, 10.1128/IAI.74.2.1016-1024.2006 Murga, 2006, Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1, Antimicrob. Agents Chemother., 50, 3289, 10.1128/AAC.00699-06 Dickson, 2006, Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease, Liver Transpl., 12, 124, 10.1002/lt.20582